Impact of the passive immunization campaign with nirsevimab in 2023–24 in Castellón. Final results

Enfermedades infecciosas y microbiologia clinica (English ed.) Pub Date : 2025-04-01 Epub Date: 2025-02-06 DOI:10.1016/j.eimce.2025.01.006

Eulalia Gregori-García , Juan Carlos Gascó-Laborda , Lledó Lluch-Bacas , Oscar Pérez-Olaso , Iris Gómez-Alfaro , Juan B. Bellido-Blasco

{"title":"Impact of the passive immunization campaign with nirsevimab in 2023–24 in Castellón. Final results","authors":"Eulalia Gregori-García , Juan Carlos Gascó-Laborda , Lledó Lluch-Bacas , Oscar Pérez-Olaso , Iris Gómez-Alfaro , Juan B. Bellido-Blasco","doi":"10.1016/j.eimce.2025.01.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>In the 2023–2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed.</div></div><div><h3>Methods</h3><div>Pre-post ecological study comparing 2023–24 vs 2022–23 season. The variation in incidence is described by age groups (0–5, 6–11 and 12–59 months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group.</div></div><div><h3>Results</h3><div>The results were very heterogeneous depending on the age group. In children 0–5 months old the RR was 0.16 (0.10–0.25); in those aged 6–11 months, RR of 0.90 (0.56–1.42); and in those aged 12–59 months, RR 1.36 (1.06–1.74). The greatest decrease in risk was in hospitalized children under 6 months, RR 0.13 (0.07–0.22).</div></div><div><h3>Conclusion</h3><div>The results support the positive impact that this campaign had, especially on hospitalizations.</div></div>","PeriodicalId":72916,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica (English ed.)","volume":"43 4","pages":"Pages 215-218"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica (English ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2529993X25000231","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

In the 2023–2024 season, systematic immunization with the monoclonal antibody nirsevimab was recommended in Spain. The impact that this immunization program had on the target population of the program is analyzed.

Methods

Pre-post ecological study comparing 2023–24 vs 2022–23 season. The variation in incidence is described by age groups (0–5, 6–11 and 12–59 months) and hospitalization. Incidence rates were calculated and relative risks (RR) were estimated for each group.

Results

The results were very heterogeneous depending on the age group. In children 0–5 months old the RR was 0.16 (0.10–0.25); in those aged 6–11 months, RR of 0.90 (0.56–1.42); and in those aged 12–59 months, RR 1.36 (1.06–1.74). The greatest decrease in risk was in hospitalized children under 6 months, RR 0.13 (0.07–0.22).

Conclusion

The results support the positive impact that this campaign had, especially on hospitalizations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

2023- 2024年使用nirseimab被动免疫运动对Castellón的影响。最终的结果。

在2023-2024季节，西班牙推荐使用单克隆抗体nirsevimab进行系统免疫。分析了该免疫规划对目标人群的影响。方法：对2023-24季和2022-23季进行前后生态对比研究。发病率的差异根据年龄组（0-5个月、6-11个月和12-59个月）和住院情况来描述。计算每组的发病率并估计相对危险度（RR）。结果：不同年龄组的结果差异很大。0 ~ 5月龄儿童的RR为0.16 (0.10 ~ 0.25)；6 ~ 11月龄，RR为0.90 (0.56 ~ 1.42)；12 ~ 59月龄的RR为1.36（1.06 ~ 1.74）。6个月以下住院儿童的风险降低幅度最大，RR为0.13（0.07-0.22）。结论：结果支持该运动产生的积极影响，特别是在住院方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Enfermedades infecciosas y microbiologia clinica (English ed.)

自引率

0.00%

发文量

期刊最新文献

An uncommon cause of tonsillar hypertrophy Evaluating a single-venipuncture strategy for blood culture collection On the treatment of Q fever Sexually transmitted infections in pregnancy: Prevalence, coinfections, and pregnancy complications. Congenital ocular toxoplasmosis: Retrospective diagnosis by PCR in heel prick blood in a pediatric case.